XML 40 R19.htm IDEA: XBRL DOCUMENT
v3.26.1

Segment Information | 6 Months Ended
--- | ---
Jun. 30, 2026
Segment Reporting [Abstract] |
Segment Information | Segment Information The Company manages its operations as a single segment focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience, and oncology. Biohaven's CEO, as the Company's chief operating decision maker, manages and allocates resources at a consolidated level. The CEO uses net loss that is also reported on the condensed consolidated statement of operations as net loss to assess performance and decide how to allocate resources. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets. Expenditures for the addition of long-lived assets are reported on the condensed consolidated statements of cash flows as purchases of property and equipment. Additional information about segment profit or loss and significant segment expenses is as follows:
|  | Three Months Ended June 30, |  | Six Months Ended June 30, |  |  |  |
|  | 2026 |  | 2025 |  | 2026 |  | 2025 |  |  |  |  |  |
Direct R&D program expense |  |  |  |  |  |  |  |  |  |  |  |  |  |
BHV-4157 (Troriluzole) |  | $ | 7,704 |  |  | $ | 14,245 |  |  | $ | 14,626 |  |  | $ | 28,033 |  |  |  |  |  |  |
BHV-2000 (Taldefgrobep Alfa) |  | 5,730 |  |  | 8,045 |  |  | 15,062 |  |  | 14,229 |  |  |  |  |  |  |
BHV-7000 & BHV-7010 (Kv7) |  | 13,845 |  |  | 31,172 |  |  | 33,578 |  |  | 62,744 |  |  |  |  |  |  |
BHV-2100 & BHV-2110 (TRPM3 Antagonist) |  | (325) |  |  | 6,845 |  |  | (530) |  |  | 23,594 |  |  |  |  |  |  |
BHV-8000 (TYK2/JAK1) |  | 4,142 |  |  | 21,216 |  |  | 9,312 |  |  | 25,589 |  |  |  |  |  |  |
BHV-1300 (IgG Degrader) |  | 9,861 |  |  | 11,732 |  |  | 11,003 |  |  | 20,352 |  |  |  |  |  |  |
BHV-1310 (IgG Degrader) |  | 15 |  |  | 3,612 |  |  | (19) |  |  | 4,686 |  |  |  |  |  |  |
BHV-1400 (IgA Degrader) |  | 11,709 |  |  | 6,737 |  |  | 16,846 |  |  | 11,597 |  |  |  |  |  |  |
BHV-1600 (β1-AR AAB Degrader) |  | (288) |  |  | 1,806 |  |  | (99) |  |  | 4,809 |  |  |  |  |  |  |
BHV-1510 (TROP-2) |  | 2,465 |  |  | 5,384 |  |  | 6,502 |  |  | 9,873 |  |  |  |  |  |  |
BHV-1530 (FGFR3) |  | 2,211 |  |  | 15,393 |  |  | 3,410 |  |  | 18,569 |  |  |  |  |  |  |
Other R&D program expense |  | 14 |  |  | 1,104 |  |  | 63 |  |  | 1,615 |  |  |  |  |  |  |
Preclinical research programs R&D Expense |  | 7,730 |  |  | 16,398 |  |  | 16,279 |  |  | 41,933 |  |  |  |  |  |  |
R&D personnel expense (excluding share-based compensation)(1) |  | 19,421 |  |  | 20,490 |  |  | 40,433 |  |  | 41,627 |  |  |  |  |  |  |
R&D Share-based compensation expense |  | 11,983 |  |  | 13,110 |  |  | 30,458 |  |  | 48,344 |  |  |  |  |  |  |
G&A personnel expense (excluding share-based compensation)(1) |  | 5,765 |  |  | 6,004 |  |  | 11,220 |  |  | 12,478 |  |  |  |  |  |  |
G&A Share-based compensation expense |  | 7,181 |  |  | 7,702 |  |  | 16,992 |  |  | 25,530 |  |  |  |  |  |  |
Other segment items (2) |  | 15,736 |  |  | 20,706 |  |  | 30,191 |  |  | 37,660 |  |  |  |  |  |  |
Non-operating expense (income) |  | 12,021 |  |  | (13,815) |  |  | 11,853 |  |  | (14,308) |  |  |  |  |  |  |
Provision for income taxes |  | 391 |  |  | 261 |  |  | 663 |  |  | 870 |  |  |  |  |  |  |
Segment net loss |  | 137,311 |  |  | 198,147 |  |  | 267,843 |  |  | 419,824 |  |  |  |  |  |  |
Reconciliation of profit or loss |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustments and reconciling items |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  |  |  |
Consolidated net loss |  | $ | 137,311 |  |  | $ | 198,147 |  |  | $ | 267,843 |  |  | $ | 419,824 |  |  |  |  |  |  |
(1) Personnel expense includes employee payroll, bonus, and employee benefits for medical care, retirement, insurances and other. (2) Other segment items included in Segment net loss include unallocated non-program R&D expense, legal, accounting and other professional service fees, rent and utilities expense, depreciation, and other corporate expenses.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for segment reporting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 18: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 19: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 20: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 22: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration